Keywords: Apeiron, Meck KGaA, Cancer biologics, License

Apeiron gets rights to Merck KGaA Ph II cancer biologics

Article | 02 February 2011

Privately-held Vienna, Austria-based biotech company Apeiron Biologics AG says it has strengthened its cancer immunotherapy portfolio by acquiring rights to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck KGaA

Go to company listing